Washington DC Washington DC: Antibody birds target a stable part of the flu virus, ensuring that immunity can oppose the new variants and provide long -term protection against aerial infections spreading globally. This helps prevent severe bird flu in monkeys.

A pathological antibody-based immune therapy protects monkeys from a serious disease caused by the H5N1 avian flu, by researchers at the University of Pittsburgh and NIH Vaccine Research Center in Science. Widely neutralized antibodies, which recognize the relatively stable area of ​​the bird flu virus, is less prone to lose its efficacy than antibodies targeting more mutation-prone structures of influenza.

This feature ensures that immunity can withstand the potential emergence of the virus variants, which developed during the Covid-19 epidemic, is similar to the Sars-Cov-2 mutant, and permanent against the aerial infections spreading globally Provides security.

Pitts School of Medicine and Center for Vaccine Research Associate Professor, Co- writer Douglas Reid, said, “This type of prevention may be very useful in controlling the outbreak of infection and preventing bird flu epidemic. ” “In our trial, antibodies performed brilliantly. Antibodies can be useful as a professional of serious illness in weak population, and it also helped us determine the test limit for antibody levels in the blood, which is a universal flu that is also a universal flu that It will be useful to judge immunity generated by the vaccine. ”

In a new study, pre-disguised monkeys with a moderate dose of widely neutralized med8852 antibodies were universally preserved against serious illness and death. In addition to confirming the efficacy of antibodies in preventing severe adverse health results, it was also able to establish its minimum serum concentrations required for scientific protection – useful measurements to determine the protective range of a potential universal flu vaccine. This research prepares a platform for the development of medical protests against future influenza virus epidemics. The serum level of adequate Med8852 for safety remained stable for 8 to 12 weeks. This suggests that, if it is given early, it can protect the first respondents and others to take care of patients at the beginning of the outbreak of H5N1.